

EAS 2020 PROGRAMME AT A GLANCE

All times are in CET (Central European Time)







Pre-recorded
with live Q&A
















Pre-recorded

Sunday 4 October 2020









12:00 – 12:05	Introduction to the scientific programme	Hall 1
13:00 – 14:30	CME Session: Prevention strategies for CV health 	Hall 1
14.30-15:30	NLA/EAS joint session: Prevention strategies for CV health 	Hall 1
15:30-17:00	CME Session: The role of TG-rich lipoproteins in atherosclerosis 	Hall 1
17:00-18:30	CME Session: Novel approaches to lipid lowering management 	Hall 1
18:30-19:00	Break	
19:00-20:30	Opening Ceremony including Anitschkow Lecture	Hall 1







Monday 5 October 2020

	Industry Session Hall	Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
08:00-08:05		Introduction to the scientific programme				
08:30 – 10:00		Plenary Session: Nature and nurture - impact of traditional risk factors, environment and genes 				
10:00 – 11:15		ESC-EAS joint symposium - A Deep Dive into ESC/EAS Dyslipidemia Guidelines 	Non-coding RNA and epigenetic regulators (Track 3: Pathogenesis of Atherosclerosis) 	Lipoprotein receptors and lipid transport (Track 2: Metabolism of Lipids and Lipoproteins) 	Who are the highest risk patients and how do we manage them? (Track 4: Prevention and Treatment of CVD) 	Immune cells in the arterial wall Session Type Track 3: Pathogenesis of Atherosclerosis 
11:30-12:00				Management of non-lipid risk factors (Track 1 - Advanced clinical seminar) 		
12:00-13:00			Rapid fire Session 1: Pathogenesis of Atherosclerosis 			









13:00-14:00			Rapid fire Session 2: Lipids and lipoprotein metabolism 			
	Industry Session Hall	Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
14:00-15:30		CME Session: Targeting lower LDL-C: When and how? 				
15:30-16:00		Break				
16:00-17:00		Late breaker session 1 				
17:00-17:30		Break				
17:30-18:30		Keynote Lecture 				
18:30 – 20:00	Industry Sponsored Session Not included in the CME/ CPD accredited programme 					



Tuesday 6 October 2020

	Industry Session Hall	Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
08:00-08:05		Introduction to the scientific programme				
08:30-10:00		Plenary Session: Understanding biology for clinical application 				
10:00 – 11:15		EAS-IAS joint session - Celebrating the 60th Anniversary of Atherosclerosis (10:00-11:00) 	Controversies in nutrition (Track 4: Prevention and Treatment of CVD) – 10:00-10:30 	Lipoproteins and the arterial wall (Track 3: Pathogenesis of Atherosclerosis) 	Lipid lowering therapies from childhood to old age (Track 4: Prevention and Treatment of CVD) 	Sterols at the crossroad of metabolic pathways (Track 2: Metabolism of Lipids and Lipoproteins) 
11:30-12:00		What is the best practice in secondary prevention in 2020? (Track 1: Advanced clinical seminar) 	NAFLD - natural history and emerging clinical trials (Track 1: Advanced clinical seminar) 			

	Industry Session Hall	Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
12:00-13:00			Rapid fire Session 3: Genetics and Epidemiology of Dyslipidemia 			
	Industry Sponsored Session Not included in the CME/CPD accredited programme (12:30-14:00) 					
13:00-14:00						
14:00-14:30	Break					
14:30-15:30	Industry Sponsored Session Not included in the CME/CPD accredited programme (14:30-15:15) 		CME Session: Implementing guidelines: a patient-centered approach for daily practice 			
15:30-16:00		Break				
16:00-17:00			Late breaker session 2 			
17:00-17:30		Break				
17:30-19:00			CME Session: New ways to modulate TG metabolic pathways 			

Wednesday 7 October 2020

	Industry Session Hall	Hall 1	Hall 2	Hall 3	Hall 4
08:00-08:05		Introduction to the scientific programme			
08:30-10:00		Plenary Session: The changing landscape in atherosclerotic vascular disease - brave new world 			
10:00 – 11:15		Plaque rupture and erosion (Track 3: Pathogenesis of Atherosclerosis) 	Cellular lipid trafficking (Track 2: Metabolism of Lipids and Lipoproteins) 	Metabolic control of fat storage and combustion (Track 2: Metabolism of Lipids and Lipoproteins) 	Strategies towards personalized risk stratification (Track 4: Prevention and Treatment of CVD) 
11:30-12:00		Risk prediction in primary prevention Track 1: Advanced clinical seminar 			
12:00-13:00			Rapid fire Session 4: Clinical Lipidology and Cardiovascular Disease 		
13:15-14:00	Industry Sponsored Session Not included in the CME/CPD accredited programme 				

	Industry Session Hall	Hall 1	Hall 2	Hall 3	Hall 4
14:00-14:30	Break				
14:30-16:00	Industry Sponsored Session Not included in the CME/CPD accredited programme 				
16:00-17:30	Industry Sponsored Session Not included in the CME/CPD accredited programme 				
17:30-19:00		CME Session: Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches 